Frontiers in Clinical Drug Research - Anti Infectives.

Format:

Book

Author/Creator:

Atta-ur-Rahman.

Contributor:

Atta-ur-Rahman, Editor.

Series:

Frontiers in Clinical Drug Research - Anti Infectives

Language:

English

Subjects (All):

Chemistry.

Physical Description:

1 online resource (367 pages)

Edition:

1st ed.

Place of Publication:

Singapore : Bentham Science Publishers, 2021.

Summary:

Frontiers in Clinical Drug Research - Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research - Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The eighth volume of this series presents comprehensive reviews of interest to readers interested in the treatment of inflammatory diseases, new antiviral agents and strategies, specific antiprotozoal drugs that work against leishmania and helminths, and a study on potential agents against American foulbrood in honey bees. The 7 reviews included in this volume are: - Monoclonal antibodies as therapeutic agents for inflammatory diseases - Pharmacotherapy of emerging antiviral agents - Antiviral activity of vitamin D and COVID-19: current understanding - Anti-infectives to combat leishmaniasis - Anthelmintic drug discovery: current situation and future perspectives - Therapeutic targets for emerging Zika virus infection and vaccines in clinical trials - Agro-industrial waste: new source of raw material for the control of American foulbrood in honey bees.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

List of Contributors

Monoclonal Antibodies as Therapeutic Agents for Inflammatory Diseases

Jéssica Bairos1,, Emanuel V. Capela1,, *, Ana P.M. Tavares1 and Mara G. Freire1

INTRODUCTION

MONOCLONAL ANTIBODIES

Structure and Properties of Antibodies

Relevance and Applications of Monoclonal Antibodies

Monoclonal Antibodies Therapeutics Market

INFLAMMATION OVERVIEW

G-Protein-Coupled Receptors

Adhesion Receptors

Pattern Recognition Receptors

Fc-Receptors

Cytokine Receptors

MONOCLONAL ANTIBODY-BASED THERAPIES FOR THE TREATMENT OF INFLAMMATION

Interleukin-8 and Interleukin-6

Anti-Interleukin-8 and Anti-Interleukin-6 mAbs

Role of Anti- IL-6 mAbs in the Severe Acute Respiratory Syndrome-2

Other Recently Approved Monoclonal Antibodies for Inflammatory Diseases

Risankizumab-rzaa

Polatuzumab Vedotin-piiq

Brolucizumab-dbll

Teprotumumab-trbw

Satralizumab-mwge

CONCLUDING REMARKS

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

Pharmacotherapy of Emerging Antiviral Agents

Gaurav M Doshi1,*, Hemen S Ved1, Ami P Thakkar1, Nirav Y. Bhatia1 and Prachi M Pimple1

EXISTING ANTIVIRAL CLASSIFICATION

5-substituted 2′-deoxyuridine Analogs

Nucleoside Analogs

Pyrophosphate Analogs

Nucleoside Reverse Transcriptase Inhibitors

Nonnucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors

Acyclic Guanosine Analogs

Acyclic Nucleoside Phosphonate Analogs

HCV NS5A/NS5B Inhibitors

HIV and HCV NS3/4A Protease Inhibitors

Integrase Inhibitors

NEWER ANTIVIRAL AGENTS

For HSV Infections

Brincidofovir

UB-621

Amenamevir (ASP2151)

Pritelivir

For HPV Infections

GX-17, NT-17

Teslexivir, AP611074, BTA074

ABI 1968.

HTI-1968

For VZV infections

FV-100, Valnivudine

For RSV Infections

MEDI8897/ Nirsevimab:

PC786

JNJ-53718678, NJ-678

JNJ-8678, Rilematovir

For HIV infections

Budigalimab

GSK3640254

UB-421

For HCV infections

Uprifosbuvir

For HBV Infections

Selgantolimod

JNJ-73763989

VIR-2218

CONCLUSION

ABBREVIATIONS

Antiviral Activity of Vitamin D and COVID 19: Current Understanding

Mahmood A. Al-Azzawi1, * and Moustafa A. Sakr2

VITAMIN D AND MICROBIAL INFECTION: INSIGHT ON MECHANISMS BASED-INHIBITION

THE ROLE OF VITAMIN D IN COVID-19 DISEASE

CLINICAL AND EPIDEMIOLOGICAL FINDINGS CONCERNING COVID-19

THE ROLE OF VITAMIN D IN COVID-19 INFECTIONS AND OUTCOMES: AN INSIGHT ON CURRENT STUDIES

RECOMMENDATIONS

CONCLUSION AND PERSPECTIVES

Anti-infectives to Combat Leishmaniasis

Shalini Roy1, Anindita Ukil1 and Pijush K. Das2,*

Leishmaniasis

Causative Parasite and the Vector

Life Cycle

Mode of Transmission

Disease Manifestations

Current Treatment Options

Evation of Host Defense

Host Resistance Factor

DRUGS FOR TREATMENT OF LEISHMANIASIS

Antimonials

Species-specific Diversity

Clinical Resistance

Advantages and Disadvantages

Amphotericin B

AmBisome

Miltefosine as Third-line Treatment

Paromomycin (Aminosidine)

Species-specific diversity

INVESTIGATIONAL DRUGS

Azoles

Species Variation

Nitroimidazole Compound

Fexinidazole

PA-824

Sitamaquine.

Nucleoside Analogues

Quinoline Derivatives

Aminoquinaldine Compounds

Naphthoquinones

Doxorubicin

OTHER INVESTIGATIONAL AGENTS

Nano-amphotericin B

Carbon Nanotubes

Oral Lipid-based Formulation of Amphotericin B

Other Amphotericin B Preparations

PRESENT SCENARIO PERTAINING TO THE USE OF THERAPEUTICS

FUTURE AGENDA FOR BETTER REMEDIAL MEASURES

New Targets, New Drugs

Cost and Distribution of Drugs

Emerging Roles of Immunomodulators

Scopes for Combinatorial Therapies

Vaccines: a Potential Therapeutic Angle

Scopes for Advancement of Techniques to Explore New Leads and Diagnostics

Anthelmintic Drug Discovery: Current Situation and Future Perspectives

María Gabriela Blanco1,2, María José De Rosa1,2,* and Diego Rayes1,2,*

INTRODUCTION TO PARASITIC NEMATODES

Helminths: Phylum Nematoda

Overview of Nematode Infections

Intestinal Infections

Tissue Infections

PARASITIC NEMATODES

Intestinal Nematodes

Ascariasis

Trichuriasis

Hookworm Infections

Strongyloidiasis

Enterobiasis

Tissue Nematodes

Filariasis

Lymphatic Filariasis (LF)

Subcutaneous Filariasis

Onchocerciasis

Loiasis

Trichinellosis

ANTHELMINTIC DRUGS

Benzimidazoles

Imidazothiazoles and Tetrahydropyrimidines

Macrocyclic Lactones

Piperazine Derivatives

Promising Drugs

Tribendimidine

Cyclooctadepsides

Pyrimidine Derivative

NEMATODE INFECTION TREATMENT

WHO and Mass Drug Administration.

THE NEED TO DEVELOP NEW ANTHELMINTIC CONTROL STRATEGIES

C. ELEGANS: A NEMATODE MODEL FOR DRUG DISCOVERY

AUTHOR CONTRIBUTIONS

LIST OF ABBREVIATIONS

Therapeutic Targets for Emerging Zika Virus Infection and Vaccines in Clinical Trials

Deepthi Ramesh1, Balaji Gowrivel Vijayakumar1 and Tharanikkarasu Kannan1,*

ZIKA VIRUS DISCOVERY AND EPIDEMIOLOGY

ZIKA VIRUS GENOME STRUCTURE AND LIFE CYCLE

Virion Structure

Viral Entry and Replication Cycle in the Host

MOLECULAR PATHOGENESIS

Zika Virus Transmission

Clinical Manifestations

Diagnostics

Prevention and Control of ZIKV Transmission

VIRAL THERAPEUTICS

Zika Virus Structural Proteins as Drug Targets

Zika Virus Nonstructural Proteins as Drug Targets

Host Cell Proteins as Drug Targets

Drug Discovery Initiatives for Treating Zika Virus Infection

Nucleoside and Nucleotide Analogs

Non-nucleoside RNA Polymerase Inhibitor

Protease Inhibitors

Fusion Inhibitors

Inhibitors of Host Nucleoside Biosynthesis

Zika Virus Vaccine

SUMMARY AND CONCLUDING REMARKS

ACKNOWLEDGEMENT

Agro-Industrial Waste: New Source of Raw Material for the Control of American Foulbrood in Honey Bees

Pablo Giménez-Martínez1,2, Cristina Ramírez3, Azucena Iglesias1,2, Florencia Fangio4, Sandra Churio4, Matias Maggi1,2 and Sandra Fuselli1,5

American Foulbrood

Characteristics of the Disease

Paenibacillus Larvae, the Causal Agent

Pathogenesis and Symptoms

Disease Control

Conventional Chemotherapy Treatment

Alternative Chemotherapy Treatment

Bioactive Compounds as an Alternative to Synthetic Antibiotics

Obtaining Plant Extracts Rich in SM.

Source of Raw Materials for Obtaining Bioactive Compounds

Humulus Lupulus L.

SECTION 1 - CHEMICAL ANALYSIS

MATERIAL AND METHODS

Vegetal Material

SolidLiquid Extraction of Bioactive Compounds

Secondary Metabolites Characterization

Statistics

RESULTS

Yield of Extraction of H. Lupulus L.

Chemical Composition Analysis

Classification of Hop Varieties

DISCUSSION

Extraction Performance of H. Lupulus L.

Effect of Fertilizer Application on the Chemical Composition of H. Lupulus L.

Chemical Analysis

Chemical Classification of Hop Varieties

SECCION 2 - BIOACTIVITY

Workplace

Paenibacillus Larvae: Strains and Culture Conditions

Honeybees

Plant Extracts, Preparation and Determination of Antimicrobial Activity

Apis Mellifera Toxicity Assay

Molecular Analysis: Effects on Bee Larvae AMP Genes

RNA Extraction

RNA Quantification

DNase Treatment

Reverse Transcript

Real-Time PCR for the Detection of the β Actin, Abaecin, Defensin-2 and Hymenoptaecin Genes

Quantitative Real-Time PCR (qPCR)

Statistic

Antimicrobial Activity of Hop Leaves (Humulus Lupulus L.)

Apis Mellifera Toxicity

Molecular Analysis

Antimicrobial Activity

Adult HoneyBees

Apis Mellifera Larvae

Effect of Fertilizer Application on the Chemical Composition of Secondary Metabolites in Hop Crops:

Analysis of Antimicrobial Activity against Paenibacillus Larvae:

Analysis of the Toxicity of Plant Extracts and Organic Compounds Analyzed in Bees (A. Mellifera)

Molecular Analysis of the Effect of the Hydroalcoholic Extract of the Victoria Variety on the Expression of Genes of the Autoimmune System in Bee larvae

ACKNOWLEDGEMENTS.

REFERENCES.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9789815039412

9815039415

OCLC:

1293258630